The goal of the CARVYKTI® REMS is to mitigate the risks of cytokine release syndrome (CRS) and neurological toxicities by:
- Ensuring that Hospitals and their Associated Clinics that dispense CARVYKTI® are specially certified and have on-site, immediate access to tocilizumab.
- Ensuring those who prescribe, dispense, or administer CARVYKTI® are aware of how to manage the risks of CRS and neurological toxicities.
Access comprehensive information on Risk Evaluation and Mitigation Strategies for CARVYKTI®. https://carvyktirems.com